Valuation : Atrion Corporation

Market Cap 81Cr 70Cr 66Cr 60Cr 112.29Cr 7.73TCr 112.86Cr 784.3Cr 301.6Cr 3.93TCr 303.99Cr 297.32Cr 12TCr P/E 2022
28.6x
P/E 2023 34.4x
Enterprise Value 80Cr 69Cr 66Cr 59Cr 111.46Cr 7.68TCr 112.02Cr 778.47Cr 299.36Cr 3.9TCr 301.73Cr 295.11Cr 12TCr EV / Sales 2022
5.27x
EV / Sales 2023 3.9x
Free-Float
50.88%
Yield 2022
1.47%
Yield 2023 2.3%
3 years 274.98
Extreme 274.98
503.24
5 years 274.98
Extreme 274.98
805.62
10 years 274.98
Extreme 274.98
948.03
Manager TitleAgeSince
Corporate Secretary 53 21/08/2024
Director TitleAgeSince
Director/Board Member 53 21/08/2024
Date Insider Type Main position Quantity % Market Cap. Importance
21/08/24 Issuer sale

Director

2,991 0.1699%
21/08/24 Issuer sale

Chief Executive Officer

98,614 5.6032%
21/08/24 Issuer sale

Director

499 0.0284%
Change 5-day change 1-year change 3-year change Capi.($)
+0.06%-.--%-.--%+1.16% 81Cr
-1.36%-6.29%-21.19%+1.21% 18TCr
-0.72%-2.30%-1.47%+13.76% 12TCr
+0.19%-4.64%+8.52%+80.96% 6.12TCr
-1.92%-7.24%+9.51%+41.28% 5.02TCr
+0.81%-5.21%-5.61%-33.33% 4.81TCr
-1.75%-7.45%+9.25%-20.43% 3.19TCr
+0.43%-11.10% - - 2.84TCr
+0.58%+1.02%+35.66%-11.94% 2.42TCr
+0.49%-8.98%-13.28%+5.27% 2.14TCr
Average -0.32%-4.66%+2.38%+8.66% 5.62TCr
Weighted average by Cap. -0.70%-4.24%-4.42%+12.05%

Financials

2022 2023
Net sales 18Cr 16Cr 15Cr 14Cr 25Cr 1.75TCr 26Cr 177.81Cr 68Cr 891.92Cr 69Cr 67Cr 2.82TCr 17Cr 15Cr 14Cr 13Cr 23Cr 1.62TCr 24Cr 164.07Cr 63Cr 823Cr 64Cr 62Cr 2.6TCr
Net income 3.5Cr 3.02Cr 2.86Cr 2.59Cr 4.86Cr 334.45Cr 4.88Cr 34Cr 13Cr 170.15Cr 13Cr 13Cr 537.67Cr 1.94Cr 1.67Cr 1.58Cr 1.44Cr 2.69Cr 185.44Cr 2.71Cr 19Cr 7.23Cr 94Cr 7.29Cr 7.13Cr 298.12Cr
Net Debt -2.52Cr -2.17Cr -2.06Cr -1.86Cr -3.5Cr -240.85Cr -3.52Cr -24Cr -9.39Cr -122.54Cr -9.47Cr -9.26Cr -387.2Cr -60.16L -51.83L -49.08L -44.49L -83.46L -57Cr -83.88L -5.83Cr -2.24Cr -29Cr -2.26Cr -2.21Cr -92Cr
Logo Atrion Corporation
Atrion Corporation develops and manufactures products, primarily for medical applications. The Company's medical products are used in a number of fields including fluid delivery, cardiovascular, and ophthalmic applications. It has developed a variety of proprietary valves designed to precisely fill, hold, and release and/or remove controlled amounts of fluids, including blood and drugs, or gasses on demand for use in areas such as intubation, intravenous, catheter, and other applications in fields including anesthesia and oncology. The core of its cardiovascular products is its Myocardial Protection System, a technology that is the only open-heart surgery system that delivers to the heart essential fluids and medications, mixes critical drugs, and controls temperature, pressure, and other important variables. The Company also manufactures a line of balloon catheters used in the treatment of nasolacrimal duct obstruction in children and adults.
Employees
712
  1. Stock Market
  2. Stocks
  3. ATRI Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!